Trial Profile
Asian Multinational Retrospective Analysis for Infectious Complications in Patients Treated With Alemtuzumab.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jan 2020
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Acute myeloid leukaemia; Aplastic anaemia; Haematological malignancies; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 22 May 2012 Actual patient number (182) and lead trial investigators added as reported by ClinicalTrials.gov.
- 22 May 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 22 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.